KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02162 KEYMED BIO-B

Market Closed 11-22 16:08:13

38.200

-1.300

-3.29%

High39.550	Low37.650	Vol774.03K
Open39.550	D1 Closing39.500	Amplitude4.81%
Mkt Cap10.69B	Tradable Cap10.69B	Total Shares279.74M
T/O29.59M	T/O Rate0.28%	Tradable Shares279.74M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"KEYMED BIO-B","latestPrice":38.2,"timestamp":1732262893016,"preClose":39.5,"halted":0,"volume":774027,"delay":0,"floatShares":279735566,"shares":279735566,"eps":-1.47424847558555,"marketStatus":"Market Closed","change":-1.3,"latestTime":"11-22 16:08:13","open":39.55,"high":39.55,"low":37.65,"amount":29591224,"amplitude":0.048101,"askPrice":38.2,"askSize":1000,"bidPrice":38,"bidSize":40500,"shortable":3,"etf":0,"ttmEps":-3.052944910678841,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732498200000},"marketStatusCode":7,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":39.5,"openAndCloseTimeList":[[1732239000000,1732248000000],[1732251600000,1732262400000]],"volumeRatio":0.7302830455289961,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162/tweets","defaultTab":"tweets","newsList":[{"id":"2484991164","title":"Keymed Biosciences Unit Grants Exclusive License for Development, Commercialization of Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2484991164","media":"MT Newswires Live","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484991164?lang=en_us&edition=fundamental","pubTime":"2024-11-19 16:32","pubTimestamp":1732005140,"startTime":"0","endTime":"0","summary":"Keymed Biosciences  unit Keymed Biosciences  has agreed to grant Platina Medicines the exclusive right to develop, manufacture, and commercialize CM336 globally, excluding Mainland China, Hong Kong, Macau, and Taiwan, a Nov. 17 bourse filing said.The drug company will receive an upfront and near-term payment of $16 million under the contract and a minority equity interest in Delaware-incorporated Ouro Medicines, the parent company of Platina Medicines.The firm may also receive additional milestone payments of up to $610 million, as well as tiered royalties on net sales of the drug and related products.Under the agreement, UK-incorporated Platina Medicines will also source clinical supply of CM336 from Keymed Biosciences.CM336 is a bispecific antibody used to treat patients with relapsed or refractory multiple myeloma.Shares of the company were up nearly 2% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1574","BK1161","BK1587","02162"],"gpt_icon":0},{"id":"2484686480","title":"BRIEF-Keymed Says Unit In License Agreement For Platina Medicines To Make Antibody CM336","url":"https://stock-news.laohu8.com/highlight/detail?id=2484686480","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484686480?lang=en_us&edition=fundamental","pubTime":"2024-11-17 18:17","pubTimestamp":1731838655,"startTime":"0","endTime":"0","summary":"BRIEF-Keymed Says Unit In License Agreement For Platina Medicines To Make Antibody CM336Nov 17  - Keymed Biosciences Inc 2162.HK:SAYS UNIT IN EXCLUSIVE LICENSE AGREEMENT FOR PLATINA MEDICINES TO MAKE BISPECIFIC ANTIBODY CM336Source textFurther company coverage: 2162.HK  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241117:nL4N3MO03D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1587","BK1161","BK1583","02162"],"gpt_icon":0},{"id":"2484145686","title":"KeyMed Biosciences  Says Unit in Exclusive License Agreement for Platina Medicines to Make Bispecific Antibody Cm336","url":"https://stock-news.laohu8.com/highlight/detail?id=2484145686","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484145686?lang=en_us&edition=fundamental","pubTime":"2024-11-17 18:17","pubTimestamp":1731838655,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241117:nL4N3MO03D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02162","BK1574","BK1583","BK1587","BK1161"],"gpt_icon":0},{"id":"2477840013","title":"Health Check: How Prudently Does Keymed Biosciences (HKG:2162) Use Debt?","url":"https://stock-news.laohu8.com/highlight/detail?id=2477840013","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477840013?lang=en_us&edition=fundamental","pubTime":"2024-10-22 07:54","pubTimestamp":1729554892,"startTime":"0","endTime":"0","summary":"Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/health-check-how-prudently-does-keymed-biosciences-hkg2162-u","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1587","BK1161","BK1574","BK1583","EBIT","02162"],"gpt_icon":0},{"id":"1123653323","title":"Stock Track | KEYMED BIO-B Stock Soars on China Approval for Atopic Dermatitis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1123653323","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123653323?lang=en_us&edition=fundamental","pubTime":"2024-09-13 22:04","pubTimestamp":1726236281,"startTime":"0","endTime":"0","summary":"Shares of KEYMED Biosciences Inc.  surged by 6.89% on Thursday after the Hong Kong-based biopharmaceutical company received a significant regulatory approval for one of its lead drug candidates.The company announced that China's National Medical Products Administration  has granted marketing approval for Stapokibart, an innovative drug used to treat moderate-to-severe atopic dermatitis in adults. This approval paves the way for KEYMED to commercialize and sell Stapokibart in the vast Chinese pha","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02162"],"gpt_icon":0},{"id":"2467748776","title":"Hong Kong Stocks Rise Amid Hopes of Mortgage Rate Cuts by China","url":"https://stock-news.laohu8.com/highlight/detail?id=2467748776","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467748776?lang=en_us&edition=fundamental","pubTime":"2024-09-13 16:53","pubTimestamp":1726217586,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["IE0002270589.USD","SHE","LU0980610538.SGD","BK0271","IE00B19Z3B42.SGD","NHLD","003816","LU1201861249.SGD","HHImain","LU0868494617.USD","LU0130103400.USD","LU0320765646.SGD","LU0477156797.USD","LU0648001328.SGD","01816","IE00BBT3K403.USD","LU0130518102.USD","LU1791807156.HKD","LU1894683348.USD","LU1363072403.SGD","BK1161","LU0648000940.SGD","LU0321505868.SGD","LU1668664300.SGD","02833","BAC","LU0310800965.SGD","LU1074936037.SGD","BK1125","BK4534","BK4207","LU0256863811.USD","IE00BFXG1179.USD","LU1280957306.USD","BK4559","513600","MCHmain","LU0106831901.USD","LU1894683264.USD","LU0149725797.USD","HSCEI","02162","BK4553","SCMP","BK1587","HSI","LU1496350171.SGD","IE00B7SZLL34.SGD","LU1201861165.SGD","BK1505"],"gpt_icon":1},{"id":"1178786344","title":"Stock Track | KEYMED BIO-B Soars on NMPA Approval for Dermatitis Drug Stapokibart","url":"https://stock-news.laohu8.com/highlight/detail?id=1178786344","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178786344?lang=en_us&edition=fundamental","pubTime":"2024-09-13 14:58","pubTimestamp":1726210717,"startTime":"0","endTime":"0","summary":"Hong Kong-based biopharmaceutical company KEYMED Biosciences Inc.  saw its stock soar by 6.89% on Thursday after receiving a major regulatory approval for one of its lead drug candidates.The company announced that China's National Medical Products Administration  has granted marketing approval for Stapokibart, an innovative drug used to treat moderate-to-severe atopic dermatitis in adults. This approval opens the door for KEYMED to commercialize and sell Stapokibart in the vast Chinese pharmaceu","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02162"],"gpt_icon":0},{"id":"2467713758","title":"Keymed Biosciences Gets Dermatitis Drug Marketing Approval From NMPA; Stocks up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2467713758","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467713758?lang=en_us&edition=fundamental","pubTime":"2024-09-13 14:57","pubTimestamp":1726210633,"startTime":"0","endTime":"0","summary":"Keymed Biosciences  said China's National Medical Products Administration  gave the marketing approval for Stapokibart, according to a Thursday filing with the Hong Kong bourse.The drug is used to treat moderate-to-severe atopic dermatitis in adults.The company's stocks were up over 5% in recent trading.Price : $39.50, Change: $+1.8, Percent Change: +4.64%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK1161","BK4585","02162","BK4526","BK4023","BK1583","HKD","BK1587","BK1574"],"gpt_icon":0},{"id":"2467713747","title":"Keymed Biosciences Gets Dermatitis Drug Marketing Approval From NMPA; Stocks up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2467713747","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467713747?lang=en_us&edition=fundamental","pubTime":"2024-09-13 14:57","pubTimestamp":1726210633,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK1587","BK4526","BK4023","HKD","NHLD","BK1161","02162","BK1583","BK4588","BK4585","BK1574"],"gpt_icon":0},{"id":"2467788650","title":"Stapokibart Was Granted Marketing Approval From National Medical Products Administration for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2467788650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467788650?lang=en_us&edition=fundamental","pubTime":"2024-09-13 00:08","pubTimestamp":1726157306,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240912:nFWN3KU1BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","BK1161","BK1587","02162"],"gpt_icon":0},{"id":"1160192213","title":"Stock Track | Keymed Bio Soars as New Cancer Drug Wins China Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1160192213","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160192213?lang=en_us&edition=fundamental","pubTime":"2024-09-12 18:32","pubTimestamp":1726137134,"startTime":"0","endTime":"0","summary":"Shares of Keymed Biosciences Inc. surged as much as 6.7% on Wednesday after the biotech company announced a major regulatory milestone for one of its leading drug candidates.The Chinese biopharmaceutical firm said its drug Stapokibart has been granted marketing approval from the National Medical Products Administration  in China. Stapokibart is a third-generation EGFR tyrosine kinase inhibitor being developed for the treatment of non-small cell lung cancer.The NMPA approval marks a significant s","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02162"],"gpt_icon":0},{"id":"2466009222","title":"BRIEF-Keymed Biosciences Says Stapokibart Was Granted Marketing Approval From China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2466009222","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466009222?lang=en_us&edition=fundamental","pubTime":"2024-09-12 18:29","pubTimestamp":1726136993,"startTime":"0","endTime":"0","summary":"Sept 12 (Reuters) - Keymed Biosciences Inc   :   * STAPOKIBART WAS GRANTED MARKETING APPROVAL FROM CHINA'S NMPA Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","02162","BK1161","BK1587"],"gpt_icon":0},{"id":"2466223822","title":"KeyMed Biosciences -  Stapokibart Was Granted Marketing Approval From China's Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2466223822","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466223822?lang=en_us&edition=fundamental","pubTime":"2024-09-12 18:16","pubTimestamp":1726136203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240912:nFWN3KU0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1161","BK1574","BK1583","02162"],"gpt_icon":0},{"id":"2462438282","title":"Keymed Biosciences Swings to Loss in H1 as Revenue Plunges 83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462438282","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462438282?lang=en_us&edition=fundamental","pubTime":"2024-08-28 16:42","pubTimestamp":1724834521,"startTime":"0","endTime":"0","summary":"Keymed Biosciences  swung to an attributable loss of 336.7 million yuan in the first half from 47.0 million yuan in the year-ago period, according to a Tuesday filing with the Hong Kong Stock Exchange.The drug company swung to a loss per share of 1.29 yuan from EPS of 0.18 yuan in the previous year.Revenue plunged 83% to 54.7 million yuan from 327.1 million yuan a year earlier.Shares rose nearly 2% on Wednesday's close.Price : $32.55, Change: $+0.50, Percent Change: +1.56%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02162"],"gpt_icon":0},{"id":"2462619822","title":"BRIEF-Keymed Biosciences Posts HY Loss RMB336.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2462619822","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462619822?lang=en_us&edition=fundamental","pubTime":"2024-08-27 21:27","pubTimestamp":1724765233,"startTime":"0","endTime":"0","summary":"Aug 27 (Reuters) - Keymed Biosciences Inc   :   * HY LOSS RMB336.6 MILLION VERSUS PROFIT RMB48.1 MILLION   * HY REVENUE RMB54.7 MILLION VERSUS RMB327.1 MILLIONFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1574","BK1583","BK1587","BK1161"],"gpt_icon":0},{"id":"2462160141","title":"KeyMed Biosciences Announces Interim Results for First Half of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2462160141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462160141?lang=en_us&edition=fundamental","pubTime":"2024-08-27 21:10","pubTimestamp":1724764256,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240827:nTUA3SXPXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1583","BK1587","BK1574","02162"],"gpt_icon":0},{"id":"2462251160","title":"Press Release: Keymed Biosciences Announces Interim Results for First Half of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2462251160","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462251160?lang=en_us&edition=fundamental","pubTime":"2024-08-27 21:10","pubTimestamp":1724764200,"startTime":"0","endTime":"0","summary":"CHENGDU, China , Aug. 27, 2024 /PRNewswire/ -- Keymed Biosciences Inc.  today announced its interim results for the first half of 2024, along with a corporate update.-- In June 2024, the long-term efficacy and safety data from the Phase III. clinical trial of Stapokibart injection for the treatment of. moderate-to-severe AD were presented by way of oral presentation at the. European Academy of Allergy and Clinical Immunology  Congress. 2024. The study showed that at week 52, the rates of achieving EASI-75. The rates of achieving an IGA score of 0 or 1 point with a reduction of. >= 2 points from baseline was 67.3%. Long-term treatment with Stapokibart. can consistently improve dermatitis symptoms and quality of life in. subjects with moderate-to-severe AD. In terms of safety, Stapokibart was. safe and well-tolerated after 52 weeks of administration, with safety. profiles consistent with those observed at week 16 and no new safety. Phase III clinical study of Stapokibart injection for th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK1587","BK1583","02162","BK1161","BK1574","SAR"],"gpt_icon":0},{"id":"2462152422","title":"KeyMed Biosciences Inc - Hy Loss RMB336.6 Mln VS Profit RMB48.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2462152422","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462152422?lang=en_us&edition=fundamental","pubTime":"2024-08-27 18:25","pubTimestamp":1724754300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240827:nFWN3KE0H1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1583","BK1161","02162","BK1574"],"gpt_icon":0},{"id":"2452263753","title":"Both retail investors who control a good portion of Keymed Biosciences Inc. (HKG:2162) along with institutions must be dismayed after last week's 6.8% decrease","url":"https://stock-news.laohu8.com/highlight/detail?id=2452263753","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452263753?lang=en_us&edition=fundamental","pubTime":"2024-07-20 06:13","pubTimestamp":1721427227,"startTime":"0","endTime":"0","summary":"Key Insights Keymed Biosciences' significant retail investors ownership suggests that the key decisions are influenced...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/both-retail-investors-who-control-a-good-portion-of-keymed-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1574","BK1587","02162","BK1583"],"gpt_icon":0},{"id":"2450786018","title":"Keymed Biosciences Grants Beleons Out-License Agreement for Bispecific Antibodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2450786018","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2450786018?lang=en_us&edition=fundamental","pubTime":"2024-07-09 17:10","pubTimestamp":1720516246,"startTime":"0","endTime":"0","summary":"Keymed Biosciences  granted Belenos Biosciences an out-license agreement for the development, manufacturing, and commercialization of Keymed's CM512 and CM536 drug candidates, according to a Tuesday filing with the Hong Kong Stock Exchange.Both CM512 and CM536 are bispecific antibodies. They bind together with targets to treat diseases such as cancer.The company, through subsidiary Keymed Biosciences , will be eligible for an upfront payment of $15 million while another subsidiary, iBridge HK Holdings, will obtain a 30.01% stake in Belenos as payment, the filing said.Chengdu Keymed will also be eligible for tiered royalties from Belenos from net sales, the filing said. Belenos will also shoulder development, regulatory, and commercialization activities for the drug outside the Greater China region.Belenos will also obtain the right to source supply for the drugs in the needed quantities for clinical trials, the filing said.Price : $32.00, Change: $+0.60, Percent Change: +1.91%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","BK4023","02162","BK1574","BK1587","HKD","BK4526","BK1161","BK1583"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0292},{"period":"1month","weight":-0.1357},{"period":"3month","weight":0.179},{"period":"6month","weight":0.1186},{"period":"1year","weight":-0.2997},{"period":"ytd","weight":-0.222}],"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0737},{"period":"3month","weight":0.0919},{"period":"6month","weight":0.0334},{"period":"1year","weight":0.0736},{"period":"ytd","weight":0.128}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Keymed Biosciences Inc is a China-based biotechnology company. The Company focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The Company has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company's main products include CM310, CM326 and CMG901.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.102216},{"month":2,"riseRate":0.666667,"avgChangeRate":0.052845},{"month":3,"riseRate":0,"avgChangeRate":-0.111304},{"month":4,"riseRate":1,"avgChangeRate":0.048679},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.125967},{"month":6,"riseRate":1,"avgChangeRate":0.150041},{"month":7,"riseRate":0.333333,"avgChangeRate":0.066538},{"month":8,"riseRate":0.5,"avgChangeRate":0.01599},{"month":9,"riseRate":0.75,"avgChangeRate":0.035232},{"month":10,"riseRate":0.5,"avgChangeRate":0.051059},{"month":11,"riseRate":0.5,"avgChangeRate":0.047496},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.129089}],"exchange":"SEHK","name":"KEYMED BIO-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest KEYMED BIO-B(02162) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"KEYMED BIO-B,02162,KEYMED BIO-B股票,KEYMED BIO-B股票老虎,KEYMED BIO-B股票老虎国际,KEYMED BIO-B行情,KEYMED BIO-B股票行情,KEYMED BIO-B股价,KEYMED BIO-B股市,KEYMED BIO-B股票价格,KEYMED BIO-B股票交易,KEYMED BIO-B股票购买,KEYMED BIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest KEYMED BIO-B(02162) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}